{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:00:29Z","timestamp":1785391229175,"version":"3.55.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Trial Information<\/jats:title>\n                  <jats:p>ClinicalTrials.gov \u00a0Identifier: \u00a0NCT00076609 Sponsor: Yiviva Inc. Principal Investigator: Yun Yen IRB Approved: Yes<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies. This traditional Chinese medicine formulation can work with Western cancer chemotherapeutic agents to improve clinical outcomes or alleviate side effects for patients with advanced HCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study aimed to evaluate efficacy and safety of capecitabine combined with a PHY906 (a pharmaceutical-grade formulation of four traditional Chinese herbs) in the treatment of advanced hepatocellular carcinoma (HCC) in Asian patients who were positive for hepatitis B virus (HBV).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was an open-label, phase II safety and efficacy clinical trial of PHY906 and capecitabine in patients with advanced HCC. Patients received 750 mg\/m2 capecitabine b.i.d. 14\u2009days plus 800 mg of PHY906 b.i.d. on days 1\u20134 and days 8\u201311 every 21-day cycle. The primary endpoint was 6-month survival rate, and secondary endpoints were progression-free survival, overall survival, disease control rate, and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-nine subjects completed the study with a 46.2% stable disease rate. The median progression-free survival was 1.5 months, and median overall survival (mOS) was 6 months with a 51.3% 6-month survival rate. The most common adverse events included lower hemoglobin, diarrhea, pain, abdomen (not otherwise specified), fatigue, increased aspartate aminotransferase, and bilirubin. Patients who (a) had not received previous chemotherapies or targeted therapy or (b) had lower starting alpha-fetoprotein (AFP) levels or (c) had HBV infection showed better clinical outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data showed that PHY906 increases the therapeutic index of capecitabine by enhancing its antitumor activity and reduces its toxicity profile in advanced HCC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13582","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T10:33:33Z","timestamp":1604399613000},"page":"e367-e373","source":"Crossref","is-referenced-by-count":41,"title":["A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma"],"prefix":"10.1093","volume":"26","author":[{"given":"Chun A.","family":"Changou","sequence":"first","affiliation":[{"name":"The PhD program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan"},{"name":"The PhD program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan"},{"name":"The Core Facility Center, Office of Research and Development, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Her-Shyong","family":"Shiah","sequence":"additional","affiliation":[{"name":"The PhD program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[{"name":"National Health Research Institutes, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servina","family":"Liu","sequence":"additional","affiliation":[{"name":"Sino-American Cancer Foundation, Covina, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Luh","sequence":"additional","affiliation":[{"name":"Sino-American Cancer Foundation, Covina, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwu-Huey","family":"Liu","sequence":"additional","affiliation":[{"name":"Yiviva Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[{"name":"The PhD program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"2021122512035438600_onco13582-bib-0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"2021122512035438600_onco13582-bib-0002","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-108-3-390","article-title":"Hepatocellular carcinoma","volume":"108","author":"Di Bisceglie","year":"1998","journal-title":"Ann Intern Med"},{"key":"2021122512035438600_onco13582-bib-0003","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention, and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021122512035438600_onco13582-bib-0004","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199306243282501","article-title":"Risk factors for hepatocellular carcinoma among patients with chronic liver disease","volume":"328","author":"Tsukuma","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122512035438600_onco13582-bib-0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: A global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021122512035438600_onco13582-bib-0006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"2021122512035438600_onco13582-bib-0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1874357901812010016","article-title":"Hepatitis C virus and hepatocellular carcinoma: Pathogenetic mechanisms and impact of direct-acting antivirals","volume":"12","author":"Schietroma","year":"2018","journal-title":"Open Virol J"},{"key":"2021122512035438600_onco13582-bib-0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602333","article-title":"A meta-analysis of case-control studies on the combined effect of hepatitis B and hepatitis C virus infections in causing hepatocellular carcinoma in China","volume":"92","author":"Shi","year":"2005","journal-title":"Br J Cancer"},{"key":"2021122512035438600_onco13582-bib-0009","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00004836-200209000-00013","article-title":"Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States","volume":"35","author":"Hassan","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"2021122512035438600_onco13582-bib-0010","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.29971","article-title":"Population attributable fractions of risk factors for hepatocellular carcinoma in the United States","volume":"122","author":"Makarova-Rusher","year":"2016","journal-title":"Cancer"},{"key":"2021122512035438600_onco13582-bib-0011","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2004.07.020","article-title":"Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study","volume":"127","author":"Davila","year":"2004","journal-title":"Gastroenterology"},{"key":"2021122512035438600_onco13582-bib-0012","first-page":"2060","article-title":"Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic status","volume":"98","author":"Di Bisceglie","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2021122512035438600_onco13582-bib-0013","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/jvh.12538","article-title":"Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma","volume":"23","author":"Lu","year":"2016","journal-title":"J Viral Hepat"},{"key":"2021122512035438600_onco13582-bib-0014","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.1994.12.6.1323","article-title":"Treatment of hepatocellular carcinoma: Too many options?","volume":"12","author":"Venook","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122512035438600_onco13582-bib-0015","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"2021122512035438600_onco13582-bib-0016","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/hep.30161","article-title":"Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology"},{"issue":"11 suppl 2","key":"2021122512035438600_onco13582-bib-0017","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/lt.21325","article-title":"Clinical and molecular classification of hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2007","journal-title":"Liver Transpl"},{"key":"2021122512035438600_onco13582-bib-0018","first-page":"378","article-title":"SHARP Investigators Study Group","volume":"359","author":"Llovet","year":"2008","journal-title":"Sorafenib in advanced hepatocellular carcinoma. N Engl J Med"},{"key":"2021122512035438600_onco13582-bib-0019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122512035438600_onco13582-bib-0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomized phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2021122512035438600_onco13582-bib-0021","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R","article-title":"Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma","volume":"89","author":"Yang","year":"2000","journal-title":"Cancer"},{"key":"2021122512035438600_onco13582-bib-0022","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdf303","article-title":"Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: A phase I-II trial","volume":"13","author":"Yang","year":"2002","journal-title":"Ann Oncol"},{"key":"2021122512035438600_onco13582-bib-0023","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/cncr.20368","article-title":"Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma","volume":"101","author":"Patt","year":"2004","journal-title":"Cancer"},{"key":"2021122512035438600_onco13582-bib-0024","first-page":"2310","article-title":"Capecitabine for treatment of advanced hepatocellular carcinoma","volume":"54","author":"von Delius","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"2021122512035438600_onco13582-bib-0025","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.dld.2016.06.037","article-title":"Capecitabine in advanced hepatocellular carcinoma","volume":"48","author":"Murer","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2021122512035438600_onco13582-bib-0026","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4603","article-title":"Phase II study of bevacizumab + capecitabine in patients with advanced\/metastatic hepatocellular carcinoma: Final report","volume":"26","author":"Hsu","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 18","key":"2021122512035438600_onco13582-bib-0027","article-title":"Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study","volume":"25","author":"Sun","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122512035438600_onco13582-bib-0028","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bcpt.12365","article-title":"The adverse effects of sorafenib in patients with advanced cancers","volume":"116","author":"Li","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2021122512035438600_onco13582-bib-0029","first-page":"85","article-title":"Sorafenib in advanced hepatocellular carcinoma: Current status and future perspectives","volume":"12","author":"Hsu","year":"2014","journal-title":"J Hepatocell Carcinoma"},{"key":"2021122512035438600_onco13582-bib-0030","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1634\/theoncologist.12-12-1425","article-title":"Hepatocellular carcinoma: The role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy","volume":"12","author":"O'Neil","year":"2007","journal-title":"The Oncologist"},{"key":"2021122512035438600_onco13582-bib-0031","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11912-008-0031-x","article-title":"The impact of new data in the treatment of advanced hepatocellular carcinoma","volume":"10","author":"Abou-Alfa","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"2021122512035438600_onco13582-bib-0032","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40264-014-0250-z","article-title":"Safety surveillance of traditional Chinese medicine: Current and future","volume":"38","author":"Liu","year":"2015","journal-title":"Drug Saf"},{"key":"2021122512035438600_onco13582-bib-0033","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jep.2012.01.047","article-title":"Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy","volume":"140","author":"Liu","year":"2012","journal-title":"J Ethnopharmacol"},{"key":"2021122512035438600_onco13582-bib-0034","volume-title":"Chinese Botany","year":"1999","edition":"1st ed"},{"key":"2021122512035438600_onco13582-bib-0035","first-page":"42","article-title":"Chinese medicine formulation, PHY-906, can enhance the therapeutic index of CPT-11 and other anticancer drugs against cancer in mice","volume":"458a","author":"Liu","year":"2001","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2021122512035438600_onco13582-bib-0036","article-title":"PHY906, a four-herb Chinese medicine formula first described 1800\u2009years ago, reduces irinotecan-induced intestinal damage through anti-inflammatory effects and by promotion of the repopulation of intestinal progenitor cells","volume":"2","author":"Lam","year":"2010","journal-title":"Sci Transl Med"},{"key":"2021122512035438600_onco13582-bib-0037","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1755-8794-4-38","article-title":"Interaction of a traditional Chinese medicine (PHY906) and CPT-11 on the inflammatory process in the tumor environment","volume":"11","author":"Wang","year":"2011","journal-title":"BMC Med Genomics"},{"key":"2021122512035438600_onco13582-bib-0038","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clcc.2011.03.003","article-title":"A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer","volume":"10","author":"Kummar","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"2021122512035438600_onco13582-bib-0039","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/1472-6882-14-490","article-title":"The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)","volume":"15","author":"Lam","year":"2014","journal-title":"BMC Complement Altern Med"},{"key":"2021122512035438600_onco13582-bib-0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.phymed.2009.12.016","article-title":"Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies","volume":"17","author":"Saif","year":"2010","journal-title":"Phytomedicine"},{"key":"2021122512035438600_onco13582-bib-0041","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation-2009.1.313","article-title":"Supplements for immune enhancement in hematologic malignancies","volume":"2009","author":"Sze","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122512035438600_onco13582-bib-0042","first-page":"22","article-title":"PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer","volume":"864a","author":"Liu","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122512035438600_onco13582-bib-0043","first-page":"47","article-title":"PHY906 as a broad-spectrum enhancer in therapy: Clinical and preclinical results in hepatocellular carcinoma","volume":"2006","author":"Liu","year":"2142","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2021122512035438600_onco13582-bib-0044","doi-asserted-by":"crossref","first-page":"9384","DOI":"10.1038\/srep09384","article-title":"PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of sorafenib by changing the tumor microenvironment","volume":"30","author":"Lam","year":"2015","journal-title":"Sci Rep"},{"issue":"suppl 7","key":"2021122512035438600_onco13582-bib-0045","first-page":"557a","article-title":"Developing PHY906 as a broad-spectrum modulator of chemotherapeutic agents in cancer therapy","volume":"64","author":"Liu","year":"2004","journal-title":"Cancer Res"},{"key":"2021122512035438600_onco13582-bib-0046","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/09553002.2012.717733","article-title":"Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy","volume":"89","author":"Rockwell","year":"2013","journal-title":"Int J Radiat Biol"},{"key":"2021122512035438600_onco13582-bib-0047","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3816\/CCC.2003.n.007","article-title":"Phase I\/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer","volume":"2","author":"Farrell","year":"2003","journal-title":"Clin Colorectal Cancer"},{"key":"2021122512035438600_onco13582-bib-0048","first-page":"4083","article-title":"Phase I\/II study of PHY906\/capecitabine in advanced hepatocellular carcinoma","volume":"29","author":"Yen","year":"2009","journal-title":"Anticancer Res"},{"key":"2021122512035438600_onco13582-bib-0049","volume-title":"A comparison of US and Taiwan phase II clinical trials on combination therapy of PHY906 plus capecitabine in hepatocellular carcinoma. Abstract presented at: 11th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM); August 21\u201323, 2012; Macau","author":"Yen"},{"issue":"suppl 5","key":"2021122512035438600_onco13582-bib-0050","doi-asserted-by":"crossref","first-page":"V90","DOI":"10.1093\/annonc\/mdy151.319","article-title":"Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer","volume":"29","author":"Johung","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122512035438600_onco13582-bib-0051","first-page":"48","article-title":"PHY906 in hepatocellular carcinoma","volume":"1841a","author":"Liu","year":"2007","journal-title":"Proc Am Assoc Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/3\/e367\/41923884\/oncolo_26_3_e367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/3\/e367\/41923884\/oncolo_26_3_e367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T12:04:46Z","timestamp":1640433886000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/3\/e367\/6445502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,25]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13582","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,25]]}}}